Molecules against Alzheimer

Dear Colleagues,

Alzheimer’s disease (AD) is a devastating disease with regard to its ever-increasing global prevalence, as well to its effects on individual patients and caregivers. Currently, it can only be treated with acetylcholinesterase inhibitors or an NMDA antagonist, but these drugs only afford a symptomatic relief for a limited time. This very modest outcome of drug development is surprising due to the many research efforts and breakthroughs in AD biochemistry and pathophysiology. Obviously, AD’s highly complex interaction of multifactorial neurodegenerative disease processes challenges medicinal chemists and drug developers.

This Special Issue aims to highlight recent efforts on the early medicinal chemistry stage of anti-Alzheimer drug development, and wants to put a special focus on innovative applications of multifunctional and hybrid molecules, as well as the use of natural products for lead identification. In this Special Issue we intend to present the most interesting examples and applications of the following topics: the design and synthesis of multipotent lead structures, the chemical basis of the development of diagnostic imaging agents, the application of natural products and their derivatives for development of neuroprotectants, rational design and related innovative approaches to AD drugs.

We welcome original articles and short communications as well as a limited number of review articles on novel methods and approaches for AD drug development. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Prof. Dr. Michael Decker
Prof. Dr. Diego Muñoz-Torrero
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.